Abstract
Protein tyrosine phosphatases (PTPs) and their inhibitors have been more and more studied during the past decades. Dephosphorylation is implicated in many biological events including the progression of the cell cycle. Around two hundred PTPs are known in humans, divided into three main groups. They all have a common amino acid sequence in their active site, referred to as the C(X)5R motif, namely a cysteine followed by five varying residues and an arginine. The CDC25 and CDC14 families are examples of PTPs described for their potential in cancer treatment, since they are key regulators of the cell cycle progression. CDC25 inhibitors have already proved their antiproliferative properties whereas the effect of the inhibition of CDC14 remains to be studied.The current review describes how the homology of the active site among the PTPs leads to similarities in their mechanism of action, regulation and inhibition. These similarities make it possible for medicinal chemists to design inhibitors based on the knowledge acquired on PTP1B inhibitors.
Keywords: Protein tyrosine phosphatases, CDC25, CDC14, PTP1B, active site, inhibitor design, enzyme inhibition
Current Enzyme Inhibition
Title: Toward Inhibitors of Protein Tyrosine Phosphatases for Cancer Treatment
Volume: 4 Issue: 1
Author(s): Alban Sidhu, Marie-Odile Contour-Galcera, Dennis Bigg and Gregoire Prevost
Affiliation:
Keywords: Protein tyrosine phosphatases, CDC25, CDC14, PTP1B, active site, inhibitor design, enzyme inhibition
Abstract: Protein tyrosine phosphatases (PTPs) and their inhibitors have been more and more studied during the past decades. Dephosphorylation is implicated in many biological events including the progression of the cell cycle. Around two hundred PTPs are known in humans, divided into three main groups. They all have a common amino acid sequence in their active site, referred to as the C(X)5R motif, namely a cysteine followed by five varying residues and an arginine. The CDC25 and CDC14 families are examples of PTPs described for their potential in cancer treatment, since they are key regulators of the cell cycle progression. CDC25 inhibitors have already proved their antiproliferative properties whereas the effect of the inhibition of CDC14 remains to be studied.The current review describes how the homology of the active site among the PTPs leads to similarities in their mechanism of action, regulation and inhibition. These similarities make it possible for medicinal chemists to design inhibitors based on the knowledge acquired on PTP1B inhibitors.
Export Options
About this article
Cite this article as:
Sidhu Alban, Contour-Galcera Marie-Odile, Bigg Dennis and Prevost Gregoire, Toward Inhibitors of Protein Tyrosine Phosphatases for Cancer Treatment, Current Enzyme Inhibition 2008; 4 (1) . https://dx.doi.org/10.2174/157340808783502559
DOI https://dx.doi.org/10.2174/157340808783502559 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cyclopamine, a Naturally Occurring Alkaloid, and Its Analogues May Find Wide Applications in Cancer Therapy
Current Topics in Medicinal Chemistry Sphingolipid Metabolism Enzymes as Targets for Anti-Cancer Therapy
Current Drug Targets Relevance of Nutritional Antioxidants in Metabolic Syndrome, Ageing and Cancer: Potential for Therapeutic Targeting
Infectious Disorders - Drug Targets Gas1 is a Pleiotropic Regulator of Cellular Functions: from Embryonic Development to Molecular Actions in Cancer Gene Therapy
Mini-Reviews in Medicinal Chemistry Subject Index To Volume 12
Current Pharmaceutical Design Recent Developments in Nanomedicines for Management of Various Health Issues Via Metabolism and Physico-Chemical Properties
Current Drug Metabolism NGS of microRNAs Involved in Cardioprotection Induced by Sevoflurane Compared to Propofol in Myocardial Revascularization Surgery: The ACDHUVV-16 Clinical Trial
Current Medicinal Chemistry Meet Our Editor
Current Metabolomics Seq and You Will Find
Current Gene Therapy Nanotechnological Strategies to Improve Water Solubility of Commercially Available Drugs
Current Nanomedicine Pharmacological Applications of Lignins and Lignins Related Compounds: An Overview
Current Organic Chemistry Molecular Markers of Angiogenesis and Metastasis in Lines of Oral Carcinoma after Treatment with Melatonin
Anti-Cancer Agents in Medicinal Chemistry The Use of the Bone Seeking Radiopharmaceutical 153-Samarium-EDTMP as an Adjuvant Treatment for Osteosarcoma: A Review
Current Medical Imaging MicroRNAs in Human Diseases
Recent Patents on DNA & Gene Sequences Protein Microarrays for Studies of Drug Mechanisms and Biomarker Discovery in the Era of Systems Biology
Current Pharmaceutical Design SCYL1-BP1 Affects Cell Cycle Arrest in Human Hepatocellular Carcinoma Cells via Cyclin F and RRM2
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors
Current Cancer Therapy Reviews Is it Possible to Reduce the Incident of Colorectal Cancer by Modifying Diet and Lifestyle?
Current Cancer Therapy Reviews Genetics of Bladder Malignant Tumors in Childhood
Current Genomics Breast Cancer: Understanding Sensitivity and Resistance to Chemotherapy and Targeted Therapies to Aid in Personalised Medicine
Current Cancer Drug Targets